SCORE

41

CGIX: Cancer Genetics, Inc. is a Sell


The current rating for CGIX is 41, which is 22% below its historic median rating of 50. This indicates higher risk than normal.


The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.